{"protocolSection": {"identificationModule": {"nctId": "NCT02836652", "orgStudyIdInfo": {"id": "SJM-CIP-10134"}, "organization": {"fullName": "Abbott Medical Devices", "class": "INDUSTRY"}, "briefTitle": "Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy", "officialTitle": "Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy", "acronym": "PREVENT II"}, "statusModule": {"statusVerifiedDate": "2022-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-02-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-07-18", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-07-12", "studyFirstSubmitQcDate": "2016-07-18", "studyFirstPostDateStruct": {"date": "2016-07-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-07-31", "resultsFirstSubmitQcDate": "2020-10-07", "resultsFirstPostDateStruct": {"date": "2020-10-29", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-06-23", "lastUpdatePostDateStruct": {"date": "2022-06-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Abbott Medical Devices", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": true, "isUsExport": true}, "descriptionModule": {"briefSummary": "This study is a prospective, multi-center, randomized, double-blind placebo-controlled study of subjects receiving the HM II LVAD as per the current FDA approved indications for use.", "detailedDescription": "This is a post-market clinical study of HM II patient management practices to be conducted in the United States.\n\nSubjects will be randomized in a 1:1 fashion to the following research drug groups:\n\n1. Treatment Arm: Warfarin (INR target: 2.0-2.5, median: 2.25) + Placebo (1 pill/day)\n2. Control Arm: Warfarin (INR target: 2.0-2.5, median: 2.25) + ASA Therapy (81mg/day)\n\nThe study will investigate if subjects in the Treatment Arm experience a reduced incidence of non-surgical bleeding, without an increased risk of thromboembolic events."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["HeartMate II (HMII)", "Left Ventricular Assist Device (LVAD)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 72, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Treatment Arm", "type": "EXPERIMENTAL", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant", "interventionNames": ["Device: HeartMate II (HMII)", "Drug: Warfarin"]}, {"label": "Control Arm", "type": "ACTIVE_COMPARATOR", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant", "interventionNames": ["Device: HeartMate II (HMII)", "Drug: Warfarin", "Drug: acetylsalicylic acid (ASA) therapy"]}], "interventions": [{"type": "DEVICE", "name": "HeartMate II (HMII)", "description": "Left Ventricular Assist Device", "armGroupLabels": ["Control Arm", "Treatment Arm"]}, {"type": "DRUG", "name": "Warfarin", "description": "(INR Target 2.0-2.5, median 2.25, per standard of patient care)", "armGroupLabels": ["Control Arm", "Treatment Arm"], "otherNames": ["Coumadin"]}, {"type": "DRUG", "name": "acetylsalicylic acid (ASA) therapy", "description": "(81mg/day)", "armGroupLabels": ["Control Arm"], "otherNames": ["Aspirin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Safety Endpoint: % of Patients With Non-surgical Bleeding at 6 Months Post HeartMate II Implant", "description": "Composite incidence of non-surgical bleeding at 6 months post initial implantation, including but not limited to gastrointestinal, genitourinary, epistaxis, subdural hematoma, and primary hemorrhagic stroke (not due to ischemic conversion, or due to the treatment of a hemolysis/suspected thrombosis event).", "timeFrame": "6 months post initial implantation"}, {"measure": "Efficacy Endpoint: % of Patients With Thromboembolic Events at 6 Months Post HeartMate II Implant", "description": "Composite incidence of pump thrombosis and thromboembolic stroke at 6 months post initial implantation, including ischemic stroke, or hemorrhagic stroke due to an ischemic conversion/treatment of hemolysis/pump thrombosis event.", "timeFrame": "6 months post initial implantation"}], "otherOutcomes": [{"measure": "Descriptive Endpoint: Percent of Patients With Adverse Events at 1-year Post HeartMate II Implant", "description": "Rates of bleeding, gastrointestinal (GI) bleeding, suspected and confirmed pump thrombosis, stroke, hemolysis, anticoagulation, survival.", "timeFrame": "12 months post-implant"}, {"measure": "Adherence to Prevention of HeartMate II Pump Thrombosis Through Clinical Management (PREVENT) Study Recommended Practices", "description": "The PREVENT recommended practices have three objectives: maximizing flow through the pump, reducing the risk of cannula malposition, and ensuring adequate anticoagulation while on left ventricular device support, with the overall goal of reducing pump thrombosis events. These implant techniques are similar to those in the HeartMate II instructions for use, but with modifications derived from clinical experience.", "timeFrame": "12 months post-implant"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria\n\n* Subject is receiving the HM II per standard of care (SOC) in accordance with the FDA approved indications for use\n* Subject is \u2265 50 years of age\n* Subject is receiving the HM II as their first LVAD\n* Subject or legally authorized representative (LAR) has signed an informed consent form (ICF).\n\nExclusion Criteria\n\n* Existence of ongoing mechanical circulatory support (MCS) other than intra-aortic balloon pump or Impella\u00ae devices\n* Participation in any other clinical investigation(s) involving an MCS device, or an investigation(s) that is likely to confound study results or affect study outcome\n* Antiplatelet therapy is mandated for other conditions, in particular: a) recent coronary artery stenting (\u2264 6 months), b) carotid artery disease, and c) other conditions where the investigator is not comfortable leaving subjects off-ASA or starting ASA post LVAD implantation. In situations where the investigator is uncertain, the Steering Committee can provide recommendation to the investigator as needed.\n* Subjects in whom heart transplantation is expected in \u2264 6 months\n* Subjects with a known ASA allergy", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "50 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Daniel Crandall", "affiliation": "Abbott", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "University of Alabama Hospital at Birmingham (UAB)", "city": "Birmingham", "state": "Alabama", "zip": "35249", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Ronald Reagan UCLA Medical Center", "city": "Los Angeles", "state": "California", "zip": "90095", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Sharp Memorial Hospital", "city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "University of California at San Francisco", "city": "San Francisco", "state": "California", "zip": "94131", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"facility": "Washington Hospital Center", "city": "Washington", "state": "District of Columbia", "zip": "20010", "country": "United States", "geoPoint": {"lat": 38.89511, "lon": -77.03637}}, {"facility": "Shands at the University of Florida", "city": "Gainesville", "state": "Florida", "zip": "32610", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Florida Hospital", "city": "Orlando", "state": "Florida", "zip": "32803", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Piedmont Hospital", "city": "Atlanta", "state": "Georgia", "zip": "30309", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "St. Vincent Hospital", "city": "Indianapolis", "state": "Indiana", "zip": "46240", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Kansas University Medical Center", "city": "Kansas City", "state": "Kansas", "zip": "66160", "country": "United States", "geoPoint": {"lat": 39.11417, "lon": -94.62746}}, {"facility": "Ochsner Medical Center", "city": "New Orleans", "state": "Louisiana", "zip": "70121", "country": "United States", "geoPoint": {"lat": 29.95465, "lon": -90.07507}}, {"facility": "Tufts Medical Center", "city": "Boston", "state": "Massachusetts", "zip": "02111", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Henry Ford Hospital", "city": "Detroit", "state": "Michigan", "zip": "48202", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "University of Minnesota Medical Center Fairview", "city": "Minneapolis", "state": "Minnesota", "zip": "55455", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Mayo Clinic", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "Montefiore Medical Center", "city": "Bronx", "state": "New York", "zip": "10467", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "New York Presbyterian Hospital/Columbia University", "city": "New York", "state": "New York", "zip": "10032", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "University of Rochester Medical Center", "city": "Rochester", "state": "New York", "zip": "14642", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "Stony Brook University Medical Center", "city": "Stony Brook", "state": "New York", "zip": "11790", "country": "United States", "geoPoint": {"lat": 40.92565, "lon": -73.14094}}, {"facility": "Westchester Medical Center", "city": "Valhalla", "state": "New York", "zip": "10595", "country": "United States", "geoPoint": {"lat": 41.07482, "lon": -73.77513}}, {"facility": "University of North Carolina at Chapel Hill", "city": "Chapel Hill", "state": "North Carolina", "zip": "27599", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}, {"facility": "Christ Hospital", "city": "Cincinnati", "state": "Ohio", "zip": "45219", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Ohio State University", "city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Integris Baptist Medical Center", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Providence St. Vincent", "city": "Portland", "state": "Oregon", "zip": "97225", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Thomas Jefferson University Hospital", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19107", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Temple University Hospital", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Palmetto Health Richland", "city": "Columbia", "state": "South Carolina", "zip": "29203", "country": "United States", "geoPoint": {"lat": 34.00071, "lon": -81.03481}}, {"facility": "Baptist Memorial Hospital", "city": "Memphis", "state": "Tennessee", "zip": "38120", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "Seton Medical Center", "city": "Austin", "state": "Texas", "zip": "78705", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Baylor University Hospital", "city": "Dallas", "state": "Texas", "zip": "75246", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Memorial Hermann", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "St. Luke's Medical Center", "city": "Milwaukee", "state": "Wisconsin", "zip": "53215", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"facility": "Institut de Cardiologie de Montreal (Montreal Heart Inst.)", "city": "Montreal", "state": "Quebec", "zip": "H1T 1C8", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Institut de Cardiologie de Quebec (H\u00f4pital Laval)", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)"}, {"id": "FG001", "title": "Aspirin", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)\n\nacetylsalicylic acid (ASA) therapy: (81mg/day)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "35"}, {"groupId": "FG001", "numSubjects": "37"}]}, {"type": "As-treated Population", "comment": "Cohort of subjects on treatment medication.", "achievements": [{"groupId": "FG000", "numSubjects": "31"}, {"groupId": "FG001", "numSubjects": "34"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "19"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Transplant/Explant", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Withdrawn", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Not on treatment regimen post-op day 15", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "As-treated population: patients that consented to participate in the study and were able to start the research drug within 15 days of HM II implant.", "groups": [{"id": "BG000", "title": "Placebo", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)"}, {"id": "BG001", "title": "Aspirin", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)\n\nacetylsalicylic acid (ASA) therapy: (81mg/day)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "65"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "68.2", "spread": "5.9"}, {"groupId": "BG001", "value": "65.6", "spread": "6.5"}, {"groupId": "BG002", "value": "66.8", "spread": "6.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "56"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "14"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "47"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "37"}, {"groupId": "BG002", "value": "72"}]}]}]}, {"title": "Ischemic Heart Failure", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "39"}]}]}]}, {"title": "History of Atrial Fibrillation", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "27"}]}]}]}, {"title": "History of Stroke", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "8"}]}]}]}, {"title": "History of Bleed", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "6"}]}]}]}, {"title": "History of Gastrointestinal Bleed", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "History of Myocardial Infarction", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "33"}]}]}]}, {"title": "History of Diabetes", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "36"}]}]}]}, {"title": "History of Aortic Stenosis", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "History of Carotid Artery Disease", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Left Ventricular Ejection Fraction (%) - mean \u00b1 standard deviation (SD)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "18.0", "spread": "5.9"}, {"groupId": "BG001", "value": "16.8", "spread": "5.1"}, {"groupId": "BG002", "value": "17.4", "spread": "5.5"}]}]}]}, {"title": "Right Atrial Pressure (mm-Hg) - mean \u00b1 SD", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm-Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10.5", "spread": "7.0"}, {"groupId": "BG001", "value": "9.6", "spread": "5.5"}, {"groupId": "BG002", "value": "10.0", "spread": "6.2"}]}]}]}, {"title": "Mean Arterial Pressure (mm-Hg) - mean \u00b1 SD", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm-Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "83.8", "spread": "10.3"}, {"groupId": "BG001", "value": "85.6", "spread": "14.2"}, {"groupId": "BG002", "value": "84.8", "spread": "12.4"}]}]}]}, {"title": "Estimated Glomerular Filtration Rate", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ml/min/1.73 m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.2", "spread": "17.3"}, {"groupId": "BG001", "value": "58.6", "spread": "22.0"}, {"groupId": "BG002", "value": "57.5", "spread": "19.8"}]}]}]}, {"title": "Destination Therapy", "description": "Destination therapy is when the device is implanted with the intent of having the device provide long-term or permanent support for the heart as opposed to being a bridge to heart transplant. The left ventricular assist device (LVAD) team makes this determination prior to the LVAD implant based on the patient's cardiac function and other comorbidities, which will also determine their eligibility for receiving a heart transplant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "57"}]}]}]}, {"title": "Inter-agency Registry for Mechanically Assisted Circulatory Support (INTERMACS) <= 3", "description": "INTERMACS profiles are commonly used to identify the severity of heart failure. Simplified definitions of profiles 1-3 are listed below.\n\n1. The patient has life-threatening hypotension, increasing need for cardiac medications and diminishing end-organ perfusion.\n2. Progressively declining nutritional intake and renal function, fluid retention, or other major status indicator, despite being on cardiac medications.\n3. The patient is stable, has normal nutritional intake, end-organ function and is not hypotensive, but is dependent on cardiac medications.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "54"}]}]}]}, {"title": "Cardiac Re-synchronization Therapy with Defibrillator", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "21"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Safety Endpoint: % of Patients With Non-surgical Bleeding at 6 Months Post HeartMate II Implant", "description": "Composite incidence of non-surgical bleeding at 6 months post initial implantation, including but not limited to gastrointestinal, genitourinary, epistaxis, subdural hematoma, and primary hemorrhagic stroke (not due to ischemic conversion, or due to the treatment of a hemolysis/suspected thrombosis event).", "populationDescription": "As-treated population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "6 months post initial implantation", "groups": [{"id": "OG000", "title": "Placebo", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)"}, {"id": "OG001", "title": "Aspirin", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)\n\nacetylsalicylic acid (ASA) therapy: (81mg/day)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "15"}]}]}]}, {"type": "PRIMARY", "title": "Efficacy Endpoint: % of Patients With Thromboembolic Events at 6 Months Post HeartMate II Implant", "description": "Composite incidence of pump thrombosis and thromboembolic stroke at 6 months post initial implantation, including ischemic stroke, or hemorrhagic stroke due to an ischemic conversion/treatment of hemolysis/pump thrombosis event.", "populationDescription": "As-treated population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "6 months post initial implantation", "groups": [{"id": "OG000", "title": "Placebo", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)"}, {"id": "OG001", "title": "Aspirin", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)\n\nacetylsalicylic acid (ASA) therapy: (81mg/day)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Descriptive Endpoint: Percent of Patients With Adverse Events at 1-year Post HeartMate II Implant", "description": "Rates of bleeding, gastrointestinal (GI) bleeding, suspected and confirmed pump thrombosis, stroke, hemolysis, anticoagulation, survival.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of subjects", "timeFrame": "12 months post-implant", "groups": [{"id": "OG000", "title": "Placebo", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)"}, {"id": "OG001", "title": "Aspirin", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)\n\nacetylsalicylic acid (ASA) therapy: (81mg/day)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "34"}]}], "classes": [{"title": "Major Bleeding", "categories": [{"measurements": [{"groupId": "OG000", "value": "38.7"}, {"groupId": "OG001", "value": "64.7"}]}]}, {"title": "GI Bleeding", "categories": [{"measurements": [{"groupId": "OG000", "value": "25.8"}, {"groupId": "OG001", "value": "29.4"}]}]}, {"title": "Ischemic Stroke", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.9"}, {"groupId": "OG001", "value": "14.7"}]}]}, {"title": "Hemorrhagic Stroke", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.5"}, {"groupId": "OG001", "value": "5.9"}]}]}, {"title": "Transient Ischemic Attack", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.7"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Hemolysis", "categories": [{"measurements": [{"groupId": "OG000", "value": "22.6"}, {"groupId": "OG001", "value": "17.6"}]}]}, {"title": "Suspected Pump Thrombosis", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.7"}, {"groupId": "OG001", "value": "8.8"}]}]}, {"title": "Confirmed Pump Thrombosis", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.5"}, {"groupId": "OG001", "value": "5.9"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Adherence to Prevention of HeartMate II Pump Thrombosis Through Clinical Management (PREVENT) Study Recommended Practices", "description": "The PREVENT recommended practices have three objectives: maximizing flow through the pump, reducing the risk of cannula malposition, and ensuring adequate anticoagulation while on left ventricular device support, with the overall goal of reducing pump thrombosis events. These implant techniques are similar to those in the HeartMate II instructions for use, but with modifications derived from clinical experience.", "populationDescription": "As-treated population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of subjects", "timeFrame": "12 months post-implant", "groups": [{"id": "OG000", "title": "Placebo", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)"}, {"id": "OG001", "title": "Aspirin", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)\n\nacetylsalicylic acid (ASA) therapy: (81mg/day)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "34"}]}], "classes": [{"title": "Was the pump pocket adequately sized?", "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "100"}]}]}, {"title": "Was the pump pocket inferiorly deep and lateral?", "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "100"}]}]}, {"title": "Was the pump positioned below the diaphragm?", "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "100"}]}]}, {"title": "Was the pump anchored?", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.7"}, {"groupId": "OG001", "value": "85.3"}]}]}, {"title": "Was inflow cannula parallel to septum and oriented", "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "100"}]}]}, {"title": "Location of core: True Apex", "categories": [{"measurements": [{"groupId": "OG000", "value": "46.7"}, {"groupId": "OG001", "value": "52.9"}]}]}, {"title": "Does the outflow graft avoid the right ventricle?", "categories": [{"measurements": [{"groupId": "OG000", "value": "93.3"}, {"groupId": "OG001", "value": "100"}]}]}, {"title": "Was Heparin Bridging started?", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.7"}, {"groupId": "OG001", "value": "85.3"}]}]}, {"title": "Was Warfarin initiated within 48 hours post HMII i", "categories": [{"measurements": [{"groupId": "OG000", "value": "66.7"}, {"groupId": "OG001", "value": "50.0"}]}]}, {"title": "Was a goal INR of 2.0 - 2.5 achieved in post-op da", "categories": [{"measurements": [{"groupId": "OG000", "value": "50.0"}, {"groupId": "OG001", "value": "26.5"}]}]}, {"title": "Was the treatment drug therapy initiated within 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.7"}, {"groupId": "OG001", "value": "73.5"}]}]}, {"title": "Pump speed <9000 leaving OR?", "categories": [{"measurements": [{"groupId": "OG000", "value": "45.2"}, {"groupId": "OG001", "value": "41.2"}]}]}, {"title": "Pump speed < 9000 at 30 days?", "categories": [{"measurements": [{"groupId": "OG000", "value": "14.3"}, {"groupId": "OG001", "value": "9.4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "At the end of study follow-up: 12-months HM II implant.", "description": "Adverse events and deaths occurring in the \"as-treated population\" are reported here. This includes patients that consented to participate in the study and were able to start the research drug within 15 days of HM II implant.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)", "deathsNumAffected": 3, "deathsNumAtRisk": 31, "seriousNumAffected": 21, "seriousNumAtRisk": 31, "otherNumAffected": 0, "otherNumAtRisk": 31}, {"id": "EG001", "title": "Aspirin", "description": "Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant\n\nHeartMate II (HMII): Left Ventricular Assist Device\n\nWarfarin: (INR Target 2.0-2.5, median 2.25, per standard of patient care)\n\nacetylsalicylic acid (ASA) therapy: (81mg/day)", "deathsNumAffected": 3, "deathsNumAtRisk": 34, "seriousNumAffected": 26, "seriousNumAtRisk": 34, "otherNumAffected": 0, "otherNumAtRisk": 34}], "seriousEvents": [{"term": "Major Bleeding", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 12, "numAtRisk": 31}, {"groupId": "EG001", "numEvents": 35, "numAffected": 22, "numAtRisk": 34}]}, {"term": "Stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 31}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 34}]}, {"term": "Hemolysis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 31}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 34}]}, {"term": "Suspected Pump Thrombosis", "organSystem": "Product Issues", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 31}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 34}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "1. The study did not complete enrollment due to competing enrollment in MOMENTUM 3.\n2. Other adverse events were not collected in this study.\n3. INR data are incomplete and hence, are not reported."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Poornima Sood", "organization": "Abbott", "email": "poornima.sood@abbott.com", "phone": "7818528334"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2020-07-16", "uploadDate": "2020-08-31T15:54", "filename": "Prot_SAP_000.pdf", "size": 4227451}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9556", "name": "Hemorrhage", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001241", "term": "Aspirin"}, {"id": "D000014859", "term": "Warfarin"}], "ancestors": [{"id": "D000000894", "term": "Anti-Inflammatory Agents, Non-Steroidal"}, {"id": "D000018712", "term": "Analgesics, Non-Narcotic"}, {"id": "D000000700", "term": "Analgesics"}, {"id": "D000018689", "term": "Sensory System Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000018501", "term": "Antirheumatic Agents"}, {"id": "D000005343", "term": "Fibrinolytic Agents"}, {"id": "D000050299", "term": "Fibrin Modulating Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000010975", "term": "Platelet Aggregation Inhibitors"}, {"id": "D000016861", "term": "Cyclooxygenase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000058633", "term": "Antipyretics"}, {"id": "D000000925", "term": "Anticoagulants"}], "browseLeaves": [{"id": "M4548", "name": "Aspirin", "asFound": "Atezolizumab", "relevance": "HIGH"}, {"id": "M17602", "name": "Warfarin", "asFound": "?", "relevance": "HIGH"}, {"id": "M4218", "name": "Anti-Inflammatory Agents, Non-Steroidal", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M4032", "name": "Analgesics", "relevance": "LOW"}, {"id": "M20786", "name": "Analgesics, Non-Narcotic", "relevance": "LOW"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}, {"id": "M8473", "name": "Fibrinolytic Agents", "relevance": "LOW"}, {"id": "M13865", "name": "Platelet Aggregation Inhibitors", "relevance": "LOW"}, {"id": "M19209", "name": "Cyclooxygenase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M29176", "name": "Antipyretics", "relevance": "LOW"}, {"id": "M4244", "name": "Anticoagulants", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Antipy", "name": "Antipyretics"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "FiAg", "name": "Fibrinolytic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnCoag", "name": "Anticoagulants"}]}}, "hasResults": true}